I've argued this before. I will again. There is enough data for...

I've argued this before. I will again. There is enough data for a deal. Any more data is asking for an unacceptable shift of risk back onto shareholders. The other risk is the ticking patent clock. The more time waiting to collect data, the less patent time left, the less value to the purchaser. If this were a US biotech, the deal would have been done many, many months ago. I hope the major shareholders are pushing McColl.